Adeno-associated virus has become the dominant vector platform for in vivo gene therapy. Behind every approved AAV gene therapy — from Luxturna to Zolgensma to Hemgenix — is a manufacturing process that depends on three plasmids working in precise coordination. Of those three, the Rep-Cap plasmid carries the most mechanistically consequential cargo. Understanding what it does, how it works, and why it matters for manufacturing quality is foundational knowledge for anyone involved in AAV development or production.
What Is a Plasmid?
A plasmid is a small, circular, double-stranded DNA molecule that exists separately from the chromosomal DNA of a cell. In nature, bacteria use plasmids to carry accessory genes — antibiotic resistance being the most well-known example. In biomanufacturing, plasmids are engineered tools: researchers design them to carry specific genetic instructions, introduce them into producer cells, and use the cell’s own machinery to read and execute those instructions.
In AAV manufacturing, plasmids are not the final product — they are the manufacturing input. The plasmids are transiently introduced into host cells, typically human embryonic kidney (HEK293) cells, where they direct the production of complete, functional viral particles. This approach, known as transient transfection, is the dominant production method for clinical and commercial AAV manufacturing and currently achieves yields in the range of 10¹⁵ to 10¹⁶ viral genomes per batch.[1]
The Three-Plasmid System
Most AAV manufacturing platforms use a three-plasmid system in which the genetic components required to produce a functional viral vector are divided across three separate DNA constructs. This separation is deliberate — it prevents any single plasmid from encoding a complete, replication-competent virus, which is a critical biosafety design principle.
The three plasmids are the transfer plasmid (also called the cis plasmid or vector genome plasmid), the helper plasmid, and the Rep-Cap plasmid. Each has a distinct and non-redundant role. The transfer plasmid carries the therapeutic gene — the sequence that will ultimately be delivered to the patient’s cells. The helper plasmid provides adenoviral helper functions that AAV requires to replicate but that are not packaged into the final vector. The Rep-Cap plasmid provides the packaging machinery — the proteins that build the viral capsid and package the therapeutic genome into it.
The Rep-Cap plasmid is the subject of this article. Its two functional elements — Rep and Cap — are encoded in overlapping reading frames on a single construct, just as they appear in the wild-type AAV genome. Their separation onto a dedicated plasmid, away from the therapeutic sequence, ensures that the replication and packaging proteins are supplied in trans without being incorporated into the vector product itself.
What the Rep Gene Does
The Rep gene encodes four proteins: Rep78, Rep68, Rep52, and Rep40. These are produced from two promoters within the Rep coding sequence and are named according to their molecular weights in kilodaltons. The larger Rep proteins — Rep78 and Rep68 — are responsible for genome replication. They recognize and bind to specific sequences in the inverted terminal repeats, the short palindromic sequences that flank the therapeutic genome on the transfer plasmid, and initiate the process of copying the single-stranded DNA genome that will be packaged into each viral particle. The smaller Rep proteins — Rep52 and Rep40 — function primarily as helicase-like motors that drive the packaged genome into the assembled capsid shell.
Without functional Rep proteins, the AAV genome cannot replicate, and genome packaging cannot occur. A deficiency or mutation in Rep produces empty capsids — viral shells with no therapeutic payload — or severely reduced vector yields. Rep protein levels must be carefully balanced: too little Rep limits genome amplification and packaging; too much Rep is cytotoxic to the producer cells and can impair overall vector yield. This balance is one of the core optimization parameters in AAV manufacturing process development.
What the Cap Gene Does
The Cap gene encodes three overlapping structural proteins — VP1, VP2, and VP3 — that form the outer protein shell of the viral particle. These three proteins are produced from a single open reading frame through alternative splicing and differential use of start codons, which is why they share a large common C-terminal sequence but have different N-terminal extensions.
Sixty VP proteins assemble together in an icosahedral structure in an approximate molar ratio of 1:1:10 (VP1:VP2:VP3), with VP1 the largest at approximately 87 kilodaltons, VP2 at 72 kilodaltons, and VP3 at 62 kilodaltons.[1] VP3, the smallest and most abundant, forms the bulk of the capsid structure. VP1 contains a unique N-terminal domain with a phospholipase A2 motif essential for endosomal escape and nuclear localization after the vector enters a target cell. VP2 serves a bridging function between VP1 and VP3 during assembly and intracellular trafficking.
The specific amino acid sequence of the VP proteins determines the serotype of the AAV vector — and serotype determines tissue tropism. AAV2 preferentially transduces retinal cells and skeletal muscle. AAV8 shows strong liver tropism and underpins hemophilia gene therapy programs. AAV9 crosses the blood-brain barrier, making it the vector of choice for CNS indications such as spinal muscular atrophy. Changing the Cap sequence on the Rep-Cap plasmid — while keeping all other plasmid components identical — produces a different serotype with different tissue targeting behavior.
This is the fundamental modular logic of AAV manufacturing: the same Rep machinery, the same helper functions, the same therapeutic gene can be combined with different Cap sequences to produce vectors with substantially different biodistribution profiles.
The Assembly Activating Protein
The Cap gene also encodes a fourth protein — the assembly activating protein (AAP) — through an overlapping reading frame embedded within the Cap coding sequence. AAP is a nuclear protein that acts as a scaffolding factor during capsid assembly, directing VP proteins to the nucleolus where capsid assembly occurs. Without AAP, capsid assembly is severely impaired. Because AAP is encoded within Cap, it is automatically co-expressed whenever the Cap sequence is present — its activity is inherent to the Cap gene rather than a separately regulated function.
Manufacturing Implications
The Rep-Cap plasmid has several direct implications for AAV manufacturing quality and consistency.
First, the ratio of Rep to Cap expression affects both vector yield and capsid integrity. Because Rep proteins are cytotoxic at high levels, manufacturers must balance productive packaging against producer cell viability over the 72 to 96-hour production window that follows transfection. Plasmid design elements — promoter strength, codon optimization, polyadenylation signals — are used to tune expression levels across this window.
Second, the Cap sequence is a primary determinant of the full/empty capsid ratio in the final product. Empty capsids — assembled protein shells containing no therapeutic genome — arise when capsid proteins assemble faster than Rep can package genomes into them. They are a major product-related impurity, and regulatory expectations require characterization and control of the full/empty ratio as a standard lot release parameter.
Third, any change to the Cap sequence — whether for serotype switching, capsid engineering, or targeted enhancement of tissue uptake — constitutes a change to the drug substance. Such changes require comparability studies and, depending on the stage of development, may require regulatory notification or filing amendments.
The Rep-Cap plasmid is not a background manufacturing component. It is a primary determinant of product identity, potency, and safety profile — which is why understanding its architecture and biology is the starting point for understanding why AAV manufacturing carries the analytical demands that it does.
[1] Penaud-Budloo M, et al. “Accurate Identification and Quantification of DNA Species by Next-Generation Sequencing in Adeno-Associated Viral Vectors Produced in Insect Cells.” Journal of Pharmaceutical Sciences. 2021. https://jpharmsci.org/article/S0022-3549(21)00193-3/fulltext